Last reviewed · How we verify
Primary hemophagocytic lymphohistiocytosis
Approved treatments
- Emapalumab-Lzsg · Swedish Orphan Biovitrum
12.1 Mechanism of Action Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted. - Gamifant · Novimmune S.A.
Gamifant works by blocking the action of interferon gamma, a protein that helps coordinate the immune response.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Primary hemophagocytic lymphohistiocytosis patent landscape — cliff calendar, originator estates, attackable patents
- Primary hemophagocytic lymphohistiocytosis treatment landscape brief
- Primary hemophagocytic lymphohistiocytosis treatment updates RSS
Frequently asked questions about Primary hemophagocytic lymphohistiocytosis
What drugs treat Primary hemophagocytic lymphohistiocytosis?
Tracked treatments include Emapalumab-Lzsg, Gamifant.
What is the treatment for Primary hemophagocytic lymphohistiocytosis?
Standard treatment for Primary hemophagocytic lymphohistiocytosis includes Emapalumab-Lzsg, Gamifant. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Primary hemophagocytic lymphohistiocytosis patent cliff · Primary hemophagocytic lymphohistiocytosis CI report
- Treatment: Emapalumab-Lzsg · Swedish Orphan Biovitrum
- Treatment: Gamifant · Novimmune S.A.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing